<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03020069</url>
  </required_header>
  <id_info>
    <org_study_id>16-01011</org_study_id>
    <nct_id>NCT03020069</nct_id>
  </id_info>
  <brief_title>Use of Continuous Glucose Monitoring System With Intensive Feedback in Adolescents With Poorly Controlled Type 1 Diabetes</brief_title>
  <official_title>Use of Continuous Glucose Monitoring System With Intensive Feedback in Adolescents With Poorly Controlled Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine that continuous glucose monitoring systems (CGMS)
      with intensive real time feedback about diabetes management from medical staff to the patient
      will affect motivation and/or behavior, in adolescents with poorly controlled type 1
      diabetes. Investigators hypothesize that short-term CGMS use with feedback (and/or lack
      thereof) and patients' sense of self-efficacy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sixty adolescents, ages 13-19 years, with type 1 diabetes and an HbA1c &gt; = 8 % who are also
      naive to CGMS use will be recruited from the diabetes outpatient population followed at
      Bellevue Hospital, Lutheran Hospital, Woodhull Hospital, and the NYU Fink Pediatric
      Ambulatory Care Center. Forty subjects will be randomly assigned to the CGMS group and 20
      subjects will be assigned to the control group.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life (Peds QL 3.2, Diabetes module)</measure>
    <time_frame>3 Months</time_frame>
    <description>33 items on a Likert scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measures of the level of glycemic control by HbA1c</measure>
    <time_frame>3 Months</time_frame>
    <description>Comparison of the glucose results (average, range, standard deviation, number of daily tests) between the study entry, 1 week, 1 month and 3 month follow up visits will be done.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measures of the level of glycemic control average glucose tests results on the patient's glucose meter</measure>
    <time_frame>3 Months</time_frame>
    <description>Comparison of the glucose results (average, range, standard deviation, number of daily tests) between the study entry, 1 week, 1 month and 3 month follow up visits will be done.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Glucose Meter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuing Glucose Monitoring Device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Glucose Meter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Average Blood glucose measure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CGMS Device</intervention_name>
    <arm_group_label>Glucose Meter</arm_group_label>
    <other_name>Continuing Glucose Monitoring Device</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Device</intervention_name>
    <arm_group_label>No Glucose Meter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 1 diabetes

          -  HbA1c &gt; = 8 %

          -  naive to CGMS use

        Exclusion Criteria:

          -  Patients with developmental delay

          -  Patients who do not use a glucose meter to test capillary blood glucose level

          -  Patients without access to a telephone will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bonita Franklin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2017</study_first_submitted>
  <study_first_submitted_qc>January 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2017</study_first_posted>
  <last_update_submitted>December 13, 2017</last_update_submitted>
  <last_update_submitted_qc>December 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>Adolescents</keyword>
  <keyword>Glucose Monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

